Pancratistatin selectively targets cancer cell mitochondria and reduces growth of human colon tumor xenografts

Molecular Cancer Therapeutics

Volumn 10, Issue 1, 2011, Pages 57-68

  Griffin, Carly ^a   Karnik, Aditya ^a   McNulty, James ^b   Pandey, Siyaram ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; BETA TUBULIN; CASPASE; DOUBLE STRANDED DNA; HISTONE H2AX; MITOCHONDRIAL DNA; PANCRATISTATIN; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL STRAIN HCT116; CELL STRAIN HT29; COLON TUMOR; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; FIBROBLAST; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY; LIVER; MALE; MICROTUBULE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; MUTANT; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR XENOGRAFT; WILD TYPE;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL DEATH; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; DNA DAMAGE; ENZYME ACTIVATION; FIBROBLASTS; HCT116 CELLS; HT29 CELLS; HUMANS; ISOQUINOLINES; MALE; MICE; MICE, NUDE; MICROTUBULES; MITOCHONDRIA; TRANSPLANTATION, HETEROLOGOUS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751518833     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0735     Document Type: Article

References (40)

1. Weekes J, Lam AK, Sebesan S, Ho YH. Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol 2009;15:3597-602.
2. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77.
3. Deorukhkar A, Krishnan S, Sethi G, Aggarwal BB. Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs 2007;16:1753-73. (Pubitemid 350187390)
4. Kornienko A, Evidente A. Chemistry, biology, and medicinal potential of narciclasine and its congeners. Chem Rev. 2008;108:1982-2014.
5. Chatterjee SJ, McNulty J, Pandey S. Sensitization of human melanoma cells by tamoxifen to apoptosis induction by pancratistatin, a nongenotoxic natural compound. Melanoma Res 2010 Mar 17. [Epub ahead of print]
6. Griffin C, Hamm C, McNulty J, Pandey S. Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on noncancerous peripheral blood mononuclear cells. Cancer Cell Int 2010;10:6.
7. Kekre N, Griffin C, McNulty J, Pandey S. Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer Chemother Pharmacol 2005;56:29-38.
8. McLachlan A, Kekre N, McNulty J, Pandey S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 2005;10:619-30.
9. Siedlakowski P, McLachlan-Burgess A, Griffin C, Tirumalai SS, McNulty J, Pandey S. Synergy of Pancratistatin and Tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biol Ther 2007;7:376-84.
10. Ravizza R, Gariboldi MB, Passarelli L, Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer 2004;4:92.
11. Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008;113Suppl:1857-87.
12. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010;31:29-59.
13. Wang F, Ogasawara MA, Huang P. Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med 2010;31:75-92.
14. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006;147:239-48.
15. Fantin VR, Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006;25:4787-97.
16. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009;458:1127-30.
17. McNulty J, Mao J, Gibe R, Mo R, Wolf S, Pettit GR, et al. Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore. Bioorg Med Chem Lett 2001;11:169-72.
18. Sandhu JK, Sodja C, McRae K, Li Y, Rippstein P, Wei YH, et al. Effects of nitric oxide donors on cybrids harbouring the mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) A3243G mitochondrial DNA mutation. Biochem J 2005; 391:191-202.
19. Gueorguieva D, Li S, Walsh N, Mukerji A, Tanha J, Pandey S. Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. FASEB J 2006;20:2636-8.
20. Pandey S, Kekre N, Naderi J, McNulty J. Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin. Artif Cells Blood Substit Immobil Biotechnol 2005;33:279-95.
21. Li H, Wu WK, Zheng Z, Che CT, Yu L, Li ZJ, et al. 2,3′,4,4′, 5′-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules. Biochem Pharmacol 2009;78:1224-32.
22. Gabrielsen B, Monath TP, Huggins JW, Kefauver DF, Pettit GR, Groszek G, et al. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod 1992;55:1569-81.
23. Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C, et al. Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. Exp Clin Cancer Res 2009;28:84.
24. Hu Y, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol 2000;60:1897-905.
25. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009;35:255-61.
26. Pradelli LA, Bénéteau M, Ricci JE. Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life. Sci 2010; 67:1589-97.
27. Constantinou C, Papas KA, Constantinou AI. Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy?Curr Cancer Drug Targets 2009;9:717-28.
28. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447-64.
29. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr Mol Med 2007;7:121-31.
30. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 2008;18:165-73.
31. DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 2008;10:767-77.
32. Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem 2008;283: 30151-63.
33. Bertholon J, Wang Q, Galmarini CM, Puisieux A. Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer 2006;5:29-34.
34. Shnyder SD, Cooper PA, Millington NJ, Gill JH, Bibby MC. Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model. J Nat Prod 2008;71:321-4.
35. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, et al. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem 2009;52:1100-14.
36. Liu J, Li Y, Tang LJ, Zhang GP, Hu WX. Treatment of lycorine on SCID mice model with human APL cells. Biomed Pharmacother 2007; 61:229-34.
37. Pettit GR, Pettit GR III, Backhaus RA, Boyd MR, Meerow AW. Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod 1993;56;1682-7.
38. Pettit GR, Ducki S, Eastham SA, Melody N. Antineoplastic agents. Synthesis of the strong cancer cell growth inhibitors trans-dihydronarciclasine and 7-deoxy-trans-dihydronarciclasine. J Nat Prod 2009;72:1279-82.
39. Pettit GR, Melody N, Herald DL. Antineoplastic agents. 511. Direct phosphorylation of phenpanstatin and pancratistatin. J Nat Prod 2004;67:322-7.
40. McNulty J, Nair JJ, Griffin C, Pandey S. Synthesis and biological evaluation of fully functionalized seco-pancratistatin analogues. J Nat Prod 2008;71:357-63.